Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. Fundamental Analysis
Ono Pharmaceutical Co., Ltd. (OPHLY) shows weak financial fundamentals with a PE ratio of 15.96, profit margin of 13.54%, and ROE of 8.61%. The company generates $523.0B in annual revenue with weak year-over-year growth of -3.14%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 59.2/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze OPHLY's fundamental strength across five key dimensions:
Efficiency Score
WeakOPHLY struggles to generate sufficient returns from assets.
Valuation Score
ExcellentOPHLY trades at attractive valuation levels.
Growth Score
WeakOPHLY faces weak or negative growth trends.
Financial Health Score
ExcellentOPHLY maintains a strong and stable balance sheet.
Profitability Score
WeakOPHLY struggles to sustain strong margins.
Key Financial Metrics
Is OPHLY Expensive or Cheap?
P/E Ratio
OPHLY trades at 15.96 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, OPHLY's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Ono Pharmaceutical Co., Ltd. at 1.32 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 8.75 times EBITDA. This is generally considered low.
How Well Does OPHLY Make Money?
Net Profit Margin
For every $100 in sales, Ono Pharmaceutical Co., Ltd. keeps $13.54 as profit after all expenses.
Operating Margin
Core operations generate 19.81 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.61 in profit for every $100 of shareholder equity.
ROA
Ono Pharmaceutical Co., Ltd. generates $6.37 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Ono Pharmaceutical Co., Ltd. generates strong operating cash flow of $140.20B, reflecting robust business health.
Free Cash Flow
Ono Pharmaceutical Co., Ltd. generates strong free cash flow of $134.20B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $95.20 in free cash annually.
FCF Yield
OPHLY converts 11.87% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
15.96
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.002
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.32
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.16
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.14
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.86
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.11
vs 25 benchmark
How OPHLY Stacks Against Its Sector Peers
| Metric | OPHLY Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 15.96 | 28.65 | Better (Cheaper) |
| ROE | 8.61% | 795.00% | Weak |
| Net Margin | 13.54% | -49787.00% (disorted) | Strong |
| Debt/Equity | 0.14 | 0.40 | Strong (Low Leverage) |
| Current Ratio | 2.86 | 3.73 | Strong Liquidity |
| ROA | 6.37% | -20255.00% (disorted) | Weak |
OPHLY outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Ono Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
78.65%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-10.06%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
19.31%
Industry Style: Defensive, Growth, Innovation
High Growth